UBS Group
TSHA icon

UBS Group’s Taysha Gene Therapies TSHA Stock Holding History

UBS Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.01M Buy
588,427
+70,729
+14% +$419K ﹤0.01% 4395
2026
Q1 		$2.31M Buy
517,698
+134,655
+35% +$626K ﹤0.01% 4844
2025
Q4 		$2.11M Sell
383,043
-256,313
-40% -$1.24M ﹤0.01% 4934
2025
Q3 		$2.09M Buy
639,356
+378,117
+145% +$1.07M ﹤0.01% 4905
2025
Q2 		$603K Sell
261,239
-156,893
-38% -$341K ﹤0.01% 5853
2025
Q1 		$581K Sell
418,132
-3,264
-0.8% -$5.46K ﹤0.01% 5734
2024
Q4 		$729K Buy
421,396
+329,395
+358% +$683K ﹤0.01% 5571
2024
Q3 		$185K Buy
92,001
+35,922
+64% +$78.8K ﹤0.01% 5936
2024
Q2 		$126K Sell
56,079
-133,205
-70% -$388K ﹤0.01% 6005
2024
Q1 		$543K Buy
189,284
+185,341
+4,701% +$386K ﹤0.01% 5131
2023
Q4 		$6.98K Buy
3,943
+3,393
+617% +$6.76K ﹤0.01% 7654
2023
Q3 		$1.74K Sell
550
-7,359
-93% -$13.7K ﹤0.01% 7844
2023
Q2 		$5.23K Buy
7,909
+4,359
+123% +$3.16K ﹤0.01% 7462
2023
Q1 		$2.83K Sell
3,550
-198,284
-98% -$256K ﹤0.01% 8432
2022
Q4 		$456K Buy
201,834
+195,562
+3,118% +$396K ﹤0.01% 4787
2022
Q3 		$12K Sell
6,272
-88,288
-93% -$320K ﹤0.01% 8186
2022
Q2 		$352K Buy
94,560
+26,580
+39% +$105K ﹤0.01% 4537
2022
Q1 		$443K Buy
67,980
+16,944
+33% +$127K ﹤0.01% 4778
2021
Q4 		$594K Buy
51,036
+17,653
+53% +$266K ﹤0.01% 4833
2021
Q3 		$622K Buy
33,383
+28,083
+530% +$534K ﹤0.01% 4571
2021
Q2 		$112K Sell
5,300
-30,911
-85% -$713K ﹤0.01% 5795
2021
Q1 		$735K Buy
36,211
+462
+1% +$12.5K ﹤0.01% 4544
2020
Q4 		$949K Buy
35,749
+24,749
+225% +$533K ﹤0.01% 4070
2020
Q3 		$247K Buy
+11,000
New +$259K ﹤0.01% 4671

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's TSHA Position: Q2 2026 in Review

UBS Group increased its Taysha Gene Therapies (TSHA) stake by 14% in Q2 2026, buying an estimated $419K and bringing the position to 588,427 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

UBS Group first reported a position in TSHA in Q3 2020 and has held it in 24 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • UBS Group held 588,427 shares of Taysha Gene Therapies worth $4.01M as of Q2 2026.
  • UBS Group bought 70,729 Taysha Gene Therapies shares in Q2 2026, an estimated $419K.
  • Taysha Gene Therapies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4395 holding.
  • UBS Group first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 24 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.